AMSbiopharma has been awarded funding by the CDTI INNTERCONECTA STEP 2025 programme for the project titled “ADVANCED ANTISENSE OLIGONUCLEOTIDE THERAPIES FOR NEUROMUSCULAR DISEASES”, NEUROAON (ITC-20251291).
The general objective of NEUROAON is to design and develop therapeutic AONs for untreated neuromuscular diseases through rational oligonucleotide design, targeted delivery, and preclinical validation. This project is subsidized by CDTI with FEDER funds 2021–2027.
This collaborative project is led by ARTHEx Biotech, with the participation of AMS Biopharma Laboratory S.L., Polypeptide Therapeutic Solutions S.L., and ProtoQsar 2000 S.L.
